Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Acta Diabetologica

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00592-011-0268-yPMID 21336872
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epitope analysis of GAD65 autoantibodies in adult-onset type 1 diabetes and latent autoimmune diabetes in adults with thyroid autoimmunity

  2011cited by this paper
• Iatrogenic diabetes mellitus during ACTH therapy in an infant with West syndrome

  2011cited by this paper
• Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN–JDRF Type 1 Diabetes Combination Therapy Assessment Group

  2010cited by this paper
• Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes!

  2010cited by this paper
• Immunotherapy of type 1 diabetes: where are we and where should we be going?

  2010cited by this paper
• The honeymoon phase: intersection of metabolism and immunology

  2009cited by this paper
• Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2

  2008cited by this paper
• Histone Deacetylase Inhibitors Modify Pancreatic Cell Fate Determination and Amplify Endocrine Progenitors

  2008cited by this paper
• FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression

  2007cited by this paper
• Deacetylase inhibition promotes the generation and function of regulatory T cells

  2007cited by this paper
• High Titer of Autoantibodies to GAD Identifies a Specific Phenotype of Adult-Onset Autoimmune Diabetes

  2007cited by this paper
• High Titer of Autoantibodies to GAD Identifies a Specific Phenotype of Adult-Onset Autoimmune Diabetes

  2007cited by this paper
• Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study

  2007cited by this paper
• Topiramate in the treatment of obese subjects with drug‐naive type 2 diabetes

  2007cited by this paper
• Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells

  2007cited by this paper
• The antiepileptic drug topiramate preserves metabolism-secretion coupling in insulin secreting cells chronically exposed to the fatty acid oleate.

  2006cited by this paper
• An association between type 1 diabetes and idiopathic generalized epilepsy

  2006cited by this paper
• IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71)

  2005cited by this paper
• Role of histone and transcription factor acetylation in diabetes pathogenesis

  2005cited by this paper
• Topiramate ameliorates hyperglycaemia and improves glucose‐stimulated insulin release in ZDF rats and db/db mice

  2005cited by this paper
• A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects

  2004cited by this paper
• C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.

  2004cited by this paper
• The Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors

  2004cited by this paper
• A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

  2004cited by this paper
• Type 1 diabetes mellitus and epilepsia partialis continua in a 6-year-old boy with elevated anti-GAD65 antibodies.

  2002cited by this paper
• Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.

  1998cited by this paper
• Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus

  1998cited by this paper
• Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus.

  1988cited by this paper

• Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis.

  2024cites this paper
• Pharmacological therapies to address obesity in type 1 diabetes.

  2020cites this paper
• CD19+IgM+ cells demonstrate enhanced therapeutic efficacy in type 1 diabetes mellitus.

  2018cites this paper
• GABA and Glutamate: Their Transmitter Role in the CNS and Pancreatic Islets

  2018cites this paper
• Carbamazepine, a beta-cell protecting drug, reduces type 1 diabetes incidence in NOD mice

  2018cites this paper
• Prevention of type 1 diabetes by carbamazepine in non-obese diabetic mice

  2017cites this paper
• Neurotransmitters and Neuropeptides: New Players in the Control of Islet of Langerhans' Cell Mass and Function

  2016cites this paper
• Antiepileptic drugs influences on body weight in people with epilepsy

  2015cites this paper
• Chapter 7 - Antiepileptic Drugs

  2014cites this paper
• Weight change, genetics and antiepileptic drugs

  2014cites this paper
• Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents

  2013cites this paper
• The potential role of glutamate in the current diabetes epidemic

  2012cites this paper
• Effects of topiramate on diabetes mellitus induced by streptozotocin in rats.

  2012cites this paper